Zydus Cadila buys out Brazilian Nikkho Pharma for $25 m

7097 Investors following Cadila Health. Share this News with them.

0

Like this story, share it with millions of investors on M3

Zydus Cadila buys out Brazilian Nikkho Pharma for $25 m

Zydus Cadila has acquired Brazil-based generic company, Nikkho Pharma, for $25 million. The Brazilian generic market is estimated at $500 million.

Post your opinion here

 

0

Tweet

Share on Tumblr

Excerpts from Markets Midday on CNBC-TV18 Watch the full show » RELATED NEWS Batliboi buys 70% stake in French co Serona buyout gives us a footprint in the US: Merck Paramount wants to fly north Cranes Software close to buying out Proland ALSO READ See latest News about Cadila Health See previous management interviews See what other Experts & Brokerages are saying about Cadila Health Cadila Health BSE | NSE 25/05/12 Are Mutual Funds betting on Cadila Health?

Zydus Cadila has acquired Brazil-based generic company, Nikkho Pharma , for $25 million.

The Brazilian industry is approximately $10-12 billion and the generic penetration in the market is estimated at only $500 million. Thus, there seems to be a lot of untapped potential in that market.

Strides Arclabs, for instance, has made approximately $65-70 million in 4-5 years. Zydus Cadila had been looking at this move for the past 7-8 months and the dule-diligence had been on for that time; and $25 million dollars and 8-9 times the EBIDTA,  it looks to be a promising market to move into, by the company.